Arbutus Biopharma Reports Final Results of Tender Offer
Arbutus Biopharma Corporation announced the final results of its tender offer to purchase for cancellation up to US$230 million of its outstanding common stock.
Arbutus Biopharma Corporation announced the final results of its tender offer to purchase for cancellation up to US$230 million of its outstanding common stock.